Cached score snapshot
US.WST · West Pharmaceutical Services
110分制 59.9/110;5D動能v2 9/50;排序分 68.9/160 · Incomplete inputs
Score breakdown
觀望
Score and price trend
Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.
Move the mouse over the chart lines to inspect readings.
- Main score
- 5D momentum v2
- Candlestick
- Historical projection
- Score turn
- Setup grade
| Model | Median | P25/P75 | 歷史相似情境上漲比例 | Down5 | Actual / compare |
|---|---|---|---|---|---|
| Rolling DOE best | +0.79% | -0.80% / +3.40% | 65% | 0% | Actual outcome pending · 1 / 3 bars observed |
| 30D observation | -0.71% | -5.12% / +1.17% | 42.5% | 25% | Actual outcome pending · 1 / 30 bars observed |
| Historical projection 10D n=160 | +0.40% | -1.71% / +2.47% | 56.3% | 3.1% | Actual outcome pending · 1 / 10 bars observed |
歷史情境統計基於已存檔相似 setup;圖中投影中位線為統計中位數的線性插值展示,並非價格路徑預測或買賣建議。
2026-07-31 → 2026-12-04 · 90 archived points · 4 Improving turn signal · 8 Deteriorating signal
Summary
score_with_momentum_v2 = main score + 5D momentum v2
Rolling setup rating
Setup quality, historical edge, and risk are combined into a rolling S/A/B/C/D/F grade for this snapshot date.
Score turn monitor
Has the score quality changed?
Run more market refreshes to build enough archived points for a turn check.
Signals
技術信號 20.7 · 資金流 15.6 · 5D動能v2 9 · Incomplete inputs
INSTITUTIONAL_DATA_OPTIONAL: Institutional ownership unavailable; neutral money-flow treatment used. FMP_INSTITUTIONAL_FAILED: FMP HTTP 402
Audit trace
Full calculation detail
Calculation detail · 8 sections
Incomplete score
此 snapshot 已計出評分,但以下輸入仍不完整;缺失維度以 0 分處理,請留意 audit 明细。
- VIX_MISSING: VIX market context is required for market environment scoring
Market inputs
Metrics snapshot
110-point main rating
基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10
基本面 — 3.2/5 · 一般
Sub-items
資金流 — 15.6/20 · 良好
Sub-items
institutional
details
warning
市場環境 — 4.6/15 · 較差
Sub-items
vix
details
trend
details
qqq
spy
催化劑 — 2/20 · 較差
Sub-items
catalyst
details
風險管理 — 7.8/10 · 良好
Sub-items
position
details
stopLevels
strength_details
diversification
details
技術信號 — 20.7/30 · 一般
Sub-items
vcpPayload
vcp_metrics
情緒分析 — 6/10 · 一般
Sub-items
sentiment
details
sentimentData
Dimension contribution
5D momentum v2 breakdown
Cursor_18.25 5D momentum v2 0-50
Risk management
position
details
stopLevels
strength_details
diversification
details
Calculation audit log
基本面分析總分: 3.2/5分 資金流分析總分: 15.6/20分 市場環境分析總分: 4.6/15分 催化劑分析: 2/20分 風險管理總分: 7.8/10分 技術信號分析總分: 20.7/30分 情緒分析: 6/10分 共振率(僅顯示不加分): 0%
Technical indicators
adx
atr
cci
cmf
kdj
mfi
obv
rsi
sar
ma50
macd
vwap
volume
derived
ma_cross
bollinger
rsi_short
macd_short
volume_ratio
Raw calculation JSON
{
"risk": {
"level": "Medium",
"reason": "risk management score >= 6.5/10",
"position": {
"score": 1.6,
"details": {
"atrPct": 2.148948161391002,
"turnoverUsdM": 281.56369281999997,
"liquidityPoints": 0.6,
"volatilityPoints": 1
}
},
"rrPoints": 1.8,
"stopLevels": {
"symbol": "US.WST",
"rr_range": "1:1.0-1:2.5",
"risk_profile": "中等",
"stop_loss_price": 375.2958,
"strength_details": {
"ma_score": 1.5,
"atr_score": 2,
"rsi_score": 3,
"macd_score": 3,
"volume_score": 2
},
"market_adjustment": 1,
"risk_reward_ratio": 1.7,
"stop_loss_percent": 4.3,
"take_profit_price": 421.1954,
"target_multiplier": 2.2,
"technical_strength": 2.35,
"take_profit_percent": 7.4
},
"positionPoints": 1.6,
"stopLossPoints": 2.4,
"diversification": {
"score": 2,
"details": {
"method": "sector concentration proxy; no portfolio holdings used",
"sector": "Health Care",
"concentratedSectorPenalty": 0
}
},
"riskRewardRatio": 1.721772570635213,
"stopLossPercent": 4.297896322782004,
"diversificationPoints": 2
},
"total": {
"max": 160,
"result": 68.9,
"formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
"baseScore": 59.9,
"modelVersion": "cursor_18_27_news_v2_160",
"momentum5dScore": 9
},
"market": {
"ma20": 376.582,
"ma50": 362.0668,
"close": 392.15,
"prevClose": 394.03,
"avgVolume20": 513335,
"volumeRatio": 1.4,
"changePercent": -0.48
},
"sources": {
"catalyst": "finnhub_news_keyword_model",
"sentiment": "finnhub_news_keyword_model",
"fundamentals": "fmp_stable",
"institutional": null,
"marketContext": "twelvedata+fred"
},
"barCount": 60,
"momentum": {
"max": 50,
"result": 9,
"details": {
"ret_5d": 0.021170775566060396,
"max_score": 50,
"max_total": 50,
"raw_total": 9,
"vcp_bonus": 0,
"vol_ratio": 1.438488585252487,
"ret_points": 4,
"vol_points": 4,
"range_ratio": 0.5126594254215875,
"volat_points": 0,
"day_range_pct": 0.011373173820557659,
"model_version": "cursor_18_27_news_v2_160",
"available_bars": 30,
"breakout_points": 0,
"partial_history": false,
"pullback_points": 1,
"breakout_vol_bonus": 0,
"first_breakout_20d": false,
"return_window_days": 5,
"first_breakout_bonus": 0,
"breakout_quality_points": 0
},
"formula": "Cursor_18.25 5D momentum v2 0-50",
"modelVersion": "cursor_18_27_news_v2_160"
},
"scoreMax": 110,
"composite": {
"max": 160,
"result": 68.9,
"formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
"weights": [
{
"raw": 3.2,
"label": "基本面",
"weight": "5/110",
"normalized": 64,
"contribution": 3.2
},
{
"raw": 15.6,
"label": "資金流",
"weight": "20/110",
"normalized": 78,
"contribution": 15.6
},
{
"raw": 4.6,
"label": "市場環境",
"weight": "15/110",
"normalized": 30.67,
"contribution": 4.6
},
{
"raw": 2,
"label": "催化劑",
"weight": "20/110",
"normalized": 10,
"contribution": 2
},
{
"raw": 7.8,
"label": "風險管理",
"weight": "10/110",
"normalized": 78,
"contribution": 7.8
},
{
"raw": 20.7,
"label": "技術信號",
"weight": "30/110",
"normalized": 69,
"contribution": 20.7
},
{
"raw": 6,
"label": "情緒分析",
"weight": "10/110",
"normalized": 60,
"contribution": 6
}
],
"modelVersion": "cursor_18_27_news_v2_160"
},
"momentumMax": 50,
"scoreStatus": "incomplete",
"standard110": {
"rating": "觀望",
"result": 59.9,
"details": [
"基本面分析總分: 3.2/5分",
"資金流分析總分: 15.6/20分",
"市場環境分析總分: 4.6/15分",
"催化劑分析: 2/20分",
"風險管理總分: 7.8/10分",
"技術信號分析總分: 20.7/30分",
"情緒分析: 6/10分",
"共振率(僅顯示不加分): 0%"
],
"formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
"dimensionScores": {
"催化劑": 2,
"基本面": 3.2,
"資金流": 15.6,
"市場環境": 4.6,
"情緒分析": 6,
"技術信號": 20.7,
"風險管理": 7.8
},
"dimensionDetails": {
"催化劑": {
"max": 20,
"grade": "較差",
"items": {
"catalyst": {
"score": 2,
"details": {
"source": "finnhub_news_keyword_model",
"articleCount": 2,
"catalystCount": 0
}
},
"catalystPoints": 2
}
},
"基本面": {
"max": 5,
"grade": "一般",
"items": {
"pbPoints": 0.2,
"pePoints": 0.2,
"epsPoints": 0,
"roePoints": 0.6,
"debtPoints": 0.5,
"marginPoints": 0.4,
"turnoverUsdM": 281.56369281999997,
"volumePoints": 0.5,
"revenuePoints": 0,
"dividendPoints": 0.3,
"marketCapPoints": 0.5
},
"source": "fmp_stable"
},
"資金流": {
"max": 20,
"grade": "良好",
"items": {
"cmfPoints": 1.6,
"mfiPoints": 4,
"obvPoints": 4,
"vwapPoints": 4,
"institutional": {
"score": 2,
"details": {
"source": "optional-neutral",
"warning": {
"code": "INSTITUTIONAL_DATA_OPTIONAL",
"symbol": "US.WST",
"message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
},
"optional": true,
"holderCount": null,
"holderPoints": 2,
"top10ShareRatio": null,
"concentrationPenalty": 0
}
},
"institutionPoints": 2
}
},
"市場環境": {
"max": 15,
"grade": "較差",
"items": {
"vix": {
"score": 0,
"details": {
"source": "twelvedata+fred",
"missing": true,
"vixClose": null
}
},
"trend": {
"score": 0.8,
"details": {
"qqq": {
"ma20": 735.23500335,
"ma50": 725.8121993399999,
"name": "QQQ",
"close": 704.40002,
"points": 0.4
},
"spy": {
"ma20": 770.1504974000001,
"ma50": 767.8083956999998,
"name": "SPY",
"close": 759.96997,
"points": 0.4
},
"source": "twelvedata+fred"
}
},
"atrPct": 2.148948161391002,
"atrPoints": 3,
"cciPoints": 0.8,
"vixPoints": 0,
"marketTrendPoints": 0.8
}
},
"情緒分析": {
"max": 10,
"grade": "一般",
"items": {
"sentiment": {
"score": 6,
"details": {
"source": "finnhub_news_keyword_model",
"articleCount": 2,
"negativeHits": 0,
"positiveHits": 1,
"sentimentScoreRaw": 1.2
}
},
"sentimentData": {
"raw": [
{
"id": 142704930,
"url": "https://finnhub.io/api/news?id=396ce0c5d19d15c2565049240f584d084b0c576b95a0294c7aeb9e87bd960d54",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "West Pharmaceutical Services has seen its share price climb sharply in recent periods, and that kind of run naturally raises a question for anyone looking at the stock today: Are the cash flows the business can generate over time enough to support where the market is currently pricing West Pharmaceutical Services? The share price has gained 37.2% over the past year, which puts a lot of weight on whether the underlying cash flows can keep backing up that move. The group’s role in supplying...",
"category": "company",
"datetime": 1791418604,
"headline": "West Pharmaceutical Services (WST) Stock Could Be 17% Overvalued As Cash Flow Falls Short"
},
{
"id": 142563086,
"url": "https://finnhub.io/api/news?id=9fe356bb8b6c323b81461cdff686ec1dca817daefb117d2d9a070c3e2998bf36",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at West Pharmaceutical Services (NYSE:WST) and the best and worst performers in the drug development inputs & services industry.",
"category": "company",
"datetime": 1790884627,
"headline": "Drug Development Inputs & Services Stocks Q2 Highlights: West Pharmaceutical Services (NYSE:WST)"
}
],
"raw_source": [
{
"id": 143012560,
"url": "https://finnhub.io/api/news?id=2ccb53addaa9d01eacfe7687646e84a97e6ee4cf6e4a9eac5b9b5469477a9e02",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "On October 19, 2026, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, declared a fourth-quarter dividend of $0.26 per share on the Company's common stock, an 18% increase over the $0.22 per share paid in the prior quarter. This is the thirty-fourth consecutive annual increase in the Company's dividend. The dividend is payable on November 18, 2026, to shareholders of record on November 11, 2026.",
"category": "company",
"datetime": 1792447440,
"headline": "West Declares Quarterly Dividend"
},
{
"id": 143025098,
"url": "https://finnhub.io/api/news?id=184da90b2ecaa23ac41e65cf4a68ca4e56b6205b3de07c9de99399644af7a9b5",
"image": "https://cdn.benzinga.com/files/images/story/2026/10/19/Monticello---Circa-June-2018-Ball-Corpor.jpg?width=2048&height=1536",
"source": "Benzinga",
"related": "WST",
"summary": "Ball Corp stock is on an 11-day winning streak, its longest since NYSE trading began in 1973, while the S&P 500 has slipped. Here is what the data shows.",
"category": "company",
"datetime": 1792422605,
"headline": "This 146-Old Can Maker Is On a Winning Streak Unseen In Its Half-Century Stock History"
},
{
"id": 143000911,
"url": "https://finnhub.io/api/news?id=9f249892f67c2c347a5af48c3b7f211933f468a1f63145c7891bc123511d8112",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.",
"category": "company",
"datetime": 1792402615,
"headline": "3 Low-Volatility Stocks We’re Skeptical Of"
},
{
"id": 142916913,
"url": "https://finnhub.io/api/news?id=e43427db7a051fa81b2854dcfd0b6bd24d6b41b26470c7092a985c1c34b6620a",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "West Pharmaceutical shares have surged 36.1% YTD, fueled by strong demand for high-value components, earnings momentum and raised guidance. Can the rally continue?",
"category": "company",
"datetime": 1792067100,
"headline": "West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally?"
},
{
"id": 142883145,
"url": "https://finnhub.io/api/news?id=cb38b4a6f60d1666f4829b94ca34f67fc98bf5704a46799c99024c3bf926f5dd",
"image": "https://cdn.benzinga.com/files/images/story/2026/10/14/Experts-Stress-Individual-Strategy.jpg?width=2048&height=1536",
"source": "Benzinga",
"related": "WST",
"summary": "CNBC traders picked WST, JPM, META and IYE; analysts raised WST and META targets, while JPM missed Q3 earnings and revenue estimates.",
"category": "company",
"datetime": 1791965393,
"headline": "Meta, JPMorgan, West Pharmaceutical And More: CNBC’s ‘Final Trades’"
},
{
"id": 142851461,
"url": "https://finnhub.io/api/news?id=01a6d2c9516083848f4715e79557defa90311fe00d1d962ba8800ec121c82bee",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "VEEV's push into early-stage biotech could unlock long-term revenue opportunities as its streamlined software solutions simplify critical drug development processes.",
"category": "company",
"datetime": 1791900180,
"headline": "Veeva Systems' Basics Gains Traction With 175+ Emerging Biotech Firms"
},
{
"id": 142852015,
"url": "https://finnhub.io/api/news?id=5c93e86e39a831dabc1abec85f4b6dda5ce3762aebf201f5f36fbb96e9de0f04",
"image": "https://image.cnbcfm.com/api/v1/image/108404206-17919110711791911068-48976902142-1080pnbcnews.jpg?v=1791911070&w=1920&h=1080",
"source": "CNBC",
"related": "WST",
"summary": "The Investment Committee gives you their top stocks to watch for the second half.",
"category": "company",
"datetime": 1791897084,
"headline": "Final Trades: JP Morgan, Meta, West Pharmaceutical Services and the iShares U.S. Energy ETF"
},
{
"id": 140020268,
"url": "https://finnhub.io/api/news?id=4f3164aa80c98143908bac684d9370239ee6fc0adb34291736a50ae401f2fc06",
"image": "",
"source": "Benzinga",
"related": "WST",
"summary": "",
"category": "company",
"datetime": 1791896442,
"headline": "Inexpensive Stocks Found In This Sector"
},
{
"id": 142883147,
"url": "https://finnhub.io/api/news?id=64790aefb0dca839b96e5a83d13b90b9b8a6e2684e44515eb2c3a5b6bcb1f488",
"image": "",
"source": "Benzinga",
"related": "WST",
"summary": "TD Cowen analyst Brendan Smith maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $410 to $420.",
"category": "company",
"datetime": 1791895217,
"headline": "TD Cowen Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $420"
},
{
"id": 142806662,
"url": "https://finnhub.io/api/news?id=88a74baf83fffd8b419bb6c42be37ea4daa59b2aa69282ceb6e60f787cf3393b",
"image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2252678669/image_2252678669.jpg?io=getty-c-w1536",
"source": "SeekingAlpha",
"related": "WST",
"summary": "Track 50 top dividend growth stocks: AMAT, DHI & HD climb as valuations shift.",
"category": "company",
"datetime": 1791722816,
"headline": "Top 50 High-Quality Dividend Growth Stocks For October 2026"
},
{
"id": 142764350,
"url": "https://finnhub.io/api/news?id=2e31d6d97a801fe996b2f4aa5b99cdc159f3a7a403533e2ccf191b9ab5afc8b7",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "AngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales.",
"category": "company",
"datetime": 1791554280,
"headline": "ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y"
},
{
"id": 142764326,
"url": "https://finnhub.io/api/news?id=68e22a1e8c5032190f9b214e0eae9f3f501a0c8427956fea9704f1ba554ec03b",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "VEEV's strong second-quarter results, Vault CRM migrations and AI expansion support growth, while market saturation remains a key concern.",
"category": "company",
"datetime": 1791553380,
"headline": "Reasons to Hold Veeva Systems Stock in Your Portfolio for Now"
},
{
"id": 142731270,
"url": "https://finnhub.io/api/news?id=0ed26bf6f6557e216075fee1446eb87ec0145d618b7bdca734d0261dab7ded7b",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "SNN expands CARTIHEAL's reach across 12 European markets, backed by five-year clinical data and strong momentum in its Sports Medicine Joint Repair business.",
"category": "company",
"datetime": 1791476280,
"headline": "Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets"
},
{
"id": 142730063,
"url": "https://finnhub.io/api/news?id=b4ec400d9af121f4582219f4a15c82ddddc99f351205421252b72488151aa5e5",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "Waters' growth outlook is fueled by strong analytical sciences demand, BD synergies and innovation, even as China weakness and integration risks persist.",
"category": "company",
"datetime": 1791465000,
"headline": "Here's Why You Should Retain WAT Stock in Your Portfolio for Now"
},
{
"id": 142720710,
"url": "https://finnhub.io/api/news?id=ce38488e0b79ff56fffbc495e662a29ddeb19bfec01bcbda355420552e85f3ee",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release third-quarter financial results before the market opens on Thursday, October 29, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time.",
"category": "company",
"datetime": 1791453600,
"headline": "West to Host Third-Quarter 2026 Conference Call"
},
{
"id": 142714392,
"url": "https://finnhub.io/api/news?id=934c43db3660d722a7b061f0cbe99e6a20e0bcbf7214dfc20f0bd48fb0f751cd",
"image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2223220663/image_2223220663.jpg?io=getty-c-w1536",
"source": "SeekingAlpha",
"related": "WST",
"summary": "West Pharmaceutical's sustained premium valuation demands proven earnings and cash flow improvements. See why I rate WST stock a Sell.",
"category": "company",
"datetime": 1791430532,
"headline": "West Pharmaceutical Services Needs Faster Earnings Growth To Justify Its Price"
},
{
"id": 142704930,
"url": "https://finnhub.io/api/news?id=396ce0c5d19d15c2565049240f584d084b0c576b95a0294c7aeb9e87bd960d54",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "West Pharmaceutical Services has seen its share price climb sharply in recent periods, and that kind of run naturally raises a question for anyone looking at the stock today: Are the cash flows the business can generate over time enough to support where the market is currently pricing West Pharmaceutical Services? The share price has gained 37.2% over the past year, which puts a lot of weight on whether the underlying cash flows can keep backing up that move. The group’s role in supplying...",
"category": "company",
"datetime": 1791418604,
"headline": "West Pharmaceutical Services (WST) Stock Could Be 17% Overvalued As Cash Flow Falls Short"
},
{
"id": 142699496,
"url": "https://finnhub.io/api/news?id=4fd1462e14a8068f02509fa6e0bf57b9d5e275828a8087a408491600e48ee514",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "FMS' transformation is lifting profitability, while HDF, value-based care and cost savings offset volume and reimbursement pressures.",
"category": "company",
"datetime": 1791394560,
"headline": "Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now"
},
{
"id": 142697379,
"url": "https://finnhub.io/api/news?id=266263d4bfc20da1cb9955c2d0af33b34d4339b28101d2e24e48433fa6b87667",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "BD plans a $19B U.S. investment, including $3B for manufacturing, to boost domestic medical consumables capacity and supply-chain resilience.",
"category": "company",
"datetime": 1791384900,
"headline": "BDX Expands U.S. Manufacturing With $19B Healthcare Investment"
},
{
"id": 142697454,
"url": "https://finnhub.io/api/news?id=82860d333e7b51aca61c43109ea92375bd0114d9fdd5bc30cc15ed3f20d662ac",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "HQY's strong HSA growth, AI-driven efficiencies and raised fiscal 2027 outlook support momentum, though cybersecurity risks remain a concern.",
"category": "company",
"datetime": 1791378660,
"headline": "Reasons to Hold HealthEquity Stock in Your Portfolio for Now"
},
{
"id": 142695123,
"url": "https://finnhub.io/api/news?id=040aecaeea9325c51813bff478015ff17a57404aa669f2cba2554f5cded4bba7",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "VEEV's DQS cleans clinical trial data for over 1 million subjects across 1,000+ studies, expanding automation in clinical data management.",
"category": "company",
"datetime": 1791377520,
"headline": "Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies"
},
{
"id": 142727972,
"url": "https://finnhub.io/api/news?id=e3b6dec0384e187508c1598eef15ccc08785eec9409efff4382a99a5292b8e99",
"image": "",
"source": "Benzinga",
"related": "WST",
"summary": "Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $400 to $440.",
"category": "company",
"datetime": 1791373126,
"headline": "Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $440"
},
{
"id": 142692942,
"url": "https://finnhub.io/api/news?id=276a8dfb6c0bab043b0f94c2eae815f8c2a8f78cda2fbe93acc8cb6978badaba",
"image": "https://media.gettyimages.com/id/2241146316/photo/close-up-of-medical-injector-on-conveyor-line-during-production-process-at-modern.jpg?b=1&s=612x612&w=0&k=20&c=xbyfAI2IEcrXsl5XxWEuMVC4MTnSwVmfug3U3nwtNWc=",
"source": "SeekingAlpha",
"related": "WST",
"summary": "West Pharma (WST) is still a buy: GLP-1 demand, HVP upgrades, and Annex 1 regulatory conversions fuel growth. Read here for a detailed analysis.",
"category": "company",
"datetime": 1791358207,
"headline": "West Pharma: Still A Buy, But Expectations Are Rising"
},
{
"id": 142665889,
"url": "https://finnhub.io/api/news?id=1d30f73b84317f4951cbffde765d910098122ab8de9b10373e2938e05df84596",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "MMSI's broad product portfolio, global expansion and strategic M&A support growth, while tariffs and China pressures remain key risks.",
"category": "company",
"datetime": 1791296220,
"headline": "Here's Why You Should Add Merit Medical Stock to Your Portfolio Now"
},
{
"id": 142665886,
"url": "https://finnhub.io/api/news?id=71d46b22fa6d97835fd0e16e258d3baec9c63b81fc3ace4de02afc7c5abd569d",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "GEHC's $945M SOFIE Biosciences deal will expand its U.S. PET radiopharmaceutical footprint and boost exposure to precision care growth.",
"category": "company",
"datetime": 1791296100,
"headline": "GE HealthCare Expands U.S. PET Radiopharma Reach With SOFIE Deal"
},
{
"id": 142665841,
"url": "https://finnhub.io/api/news?id=7684ab149c75a6611241a6e241b1447bfb4abc3df76fac2245282768a6c23163",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "CAH enters fiscal 2027 with Pharma profit growth, emerging growth engines and efficiency gains offsetting revenue headwinds.",
"category": "company",
"datetime": 1791294240,
"headline": "Reasons to Retain Cardinal Health Stock in Your Portfolio for Now"
},
{
"id": 142637944,
"url": "https://finnhub.io/api/news?id=3225700f0000186448e0c48a8bcfc72bf29c6dbd189622c3e4101d0032e609ca",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "DOCS' rapid clinical AI adoption and strong cash generation support its outlook, but tight pharma budgets and AI costs may limit near-term gains.",
"category": "company",
"datetime": 1791212760,
"headline": "Reasons to Retain Doximity Stock in Your Portfolio for Now"
},
{
"id": 142637260,
"url": "https://finnhub.io/api/news?id=216b3e60a44c986014f03b75bac5ad080205b157548e71f937d483dbf25099e8",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "VEEV's OpenData deal with Servier across 80+ countries strengthens its Data Cloud role as life sciences firms scale AI and advanced analytics.",
"category": "company",
"datetime": 1791212160,
"headline": "Veeva's OpenData to Help Servier Build a Global AI Data Foundation"
},
{
"id": 142636954,
"url": "https://finnhub.io/api/news?id=1f77c39883a9badee4aa990a5a3ba091bade1d44a2219c6b9579dcec43b2ea63",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "INSP gains new Category I CPT codes for Inspire V procedures, creating a dedicated coding framework effective Jan. 1, 2028.",
"category": "company",
"datetime": 1791211920,
"headline": "Inspire Medical Gains New CPT Codes for Hypoglossal Nerve Stimulation"
},
{
"id": 142637943,
"url": "https://finnhub.io/api/news?id=f01435598b72cb037c02282b97ed1dded7390ba1ba3d381a6e160139cb4c981a",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "West Pharmaceutical Services will release its third-quarter earnings soon, and analysts anticipate a low double-digit bottom-line growth.",
"category": "company",
"datetime": 1791199301,
"headline": "What to Expect From West Pharmaceutical Services' Next Quarterly Earnings Report"
},
{
"id": 142633169,
"url": "https://finnhub.io/api/news?id=dc33fe661d7c2c3492f14647b52b156ae627758638cd09a354c63940fe379d75",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced its participation in CPHI Worldwide in Milan, Italy, where it will highlight its leadership and expertise in addressing industry challenges.",
"category": "company",
"datetime": 1791194400,
"headline": "West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide"
},
{
"id": 142631137,
"url": "https://finnhub.io/api/news?id=260b9b916255acd521ef0477decef09d37087460a3eb5277e2f8edb1bfb44ddb",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.",
"category": "company",
"datetime": 1791189780,
"headline": "1 Cash-Producing Stock on Our Buy List and 2 Facing Challenges"
},
{
"id": 142563086,
"url": "https://finnhub.io/api/news?id=9fe356bb8b6c323b81461cdff686ec1dca817daefb117d2d9a070c3e2998bf36",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at West Pharmaceutical Services (NYSE:WST) and the best and worst performers in the drug development inputs & services industry.",
"category": "company",
"datetime": 1790884627,
"headline": "Drug Development Inputs & Services Stocks Q2 Highlights: West Pharmaceutical Services (NYSE:WST)"
},
{
"id": 142765025,
"url": "https://finnhub.io/api/news?id=6f3b40d9ecb8b2f445bc3546fe3407cec280820da805bba4bc1a2509006e1632",
"image": "https://image.cnbcfm.com/api/v1/image/108371167-1790873083887-1790872950-48726431161-hd.jpg?v=1790873085&w=1920&h=1080",
"source": "CNBC",
"related": "WST",
"summary": "Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's \"Halftime Report\" to spotlight West Pharmaceutical Services in his \"Best Stocks in the Market.\"",
"category": "company",
"datetime": 1790858700,
"headline": "Josh Brown's 'Best Stocks in the Market:' West Pharmaceutical Services"
},
{
"id": 142522216,
"url": "https://finnhub.io/api/news?id=90a057d79e8667db4d4ec9352646ed98e0292cae1df0b8ed83de6346aa944120",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "SNN expands its trauma portfolio with the EVOS PELVIC System, targeting complex pelvic and acetabular fracture procedures in the United States.",
"category": "company",
"datetime": 1790787180,
"headline": "Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care"
},
{
"id": 142498423,
"url": "https://finnhub.io/api/news?id=7064296f2ba9b30ab472588b5aec14b5e58d924cc5cd7bd7f0ea0eed807ad14c",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "ITGR's $127-a-share KKR deal offers defined cash value, while core franchises face slow new-product adoption.",
"category": "company",
"datetime": 1790690640,
"headline": "Here's Why You Should Retain Integer Holdings Stock in Your Portfolio"
},
{
"id": 142469358,
"url": "https://finnhub.io/api/news?id=df6606a47f06bf41c262e3c74d80e5e1a9270c0e6b943a74aeee5a7d769eac3c",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "Becton, Dickinson's MedTech transformation, innovation pipeline and strategic partnerships support growth despite reimbursement and macroeconomic pressures.",
"category": "company",
"datetime": 1790608500,
"headline": "Here's Why You Should Retain BDX Stock in Your Portfolio for Now"
},
{
"id": 142453159,
"url": "https://finnhub.io/api/news?id=a858de7c4755f727def1d938c4a395431e61d53c9193adecc8cfe68e25951e21",
"image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2260312486/image_2260312486.jpg?io=getty-c-w1536",
"source": "SeekingAlpha",
"related": "WST",
"summary": "The ProShares S&P 500 Dividend Aristocrats ETF trails SPY YTD, but 20 individual Aristocrats are outperforming the ETF. Check out the Aristocrats list here.",
"category": "company",
"datetime": 1790556963,
"headline": "Best Dividend Aristocrats For October 2026"
},
{
"id": 142424949,
"url": "https://finnhub.io/api/news?id=6dbd079c7174f0bb58e0ab95c6ace326965052422fd0cba48bd7af8b47011eb1",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WST",
"summary": "VEEV's AI-powered Study Builder Agent automates clinical study setup, cutting manual work while strengthening its connected Clinical Data ecosystem.",
"category": "company",
"datetime": 1790347980,
"headline": "Veeva Unveils AI Study Builder Agent to Speed Clinical Trial Setup"
}
],
"data_source": "finnhub_news_keyword_model",
"article_count": 2,
"negative_hits": 0,
"positive_hits": 1,
"recomputed_at_score": true,
"sentiment_score_raw": 1.2,
"source_article_count": 39,
"discarded_article_count": 37
},
"sentimentPoints": 6
}
},
"技術信號": {
"max": 30,
"raw": 20.7,
"grade": "一般",
"items": {
"bbPoints": 3,
"adxPoints": 3,
"sarPoints": 2.4000000000000004,
"vcpPoints": 0.4,
"macdPoints": 4,
"vcpPayload": {
"vcp_pass": false,
"vcp_score": 0.4,
"vcp_reason": "站上MA50;Ready=N;Confirm=N",
"vcp_metrics": {
"up_days": 8,
"vol_ref": 583796.6666666666,
"down_days": 1,
"vcp_ready": false,
"above_ma50": true,
"avg_vol_10": 482740,
"avg_vol_20": 499135,
"avg_vol_30": 583796.6666666666,
"range_pct_10": 0.08920058878491888,
"range_pct_20": 0.09606020900319301,
"range_pct_30": 0.14147650494648756,
"up_expand_ok": false,
"lookback_used": 59,
"near_20d_high": true,
"contraction_ok": false,
"down_shrink_ok": false,
"up_expand_days": 1,
"breakout_20d_ok": false,
"vol_ratio_10_30": 0.8268974928485375,
"dist_to_20d_high": 0.012614588578910318,
"down_shrink_days": 1,
"breakout_level_20d": 397.16,
"vcp_breakout_confirm": false,
"contraction_ratio_10_30": 0.6304975431691526
},
"vcp_name_en": "Volatility Contraction Pattern",
"vcp_name_zh": "波動收縮形態",
"vol_contraction": false
},
"kdjAdxPoints": 0.7,
"rsiKdjPoints": 3.2,
"volumeWeight": 2,
"maCrossPoints": 1.6,
"shortRsiPoints": 0.8,
"shortMacdPoints": 0.4,
"volConfirmPoints": 0,
"volumePointsTechnical": 1.2
}
},
"風險管理": {
"max": 10,
"grade": "良好",
"items": {
"position": {
"score": 1.6,
"details": {
"atrPct": 2.148948161391002,
"turnoverUsdM": 281.56369281999997,
"liquidityPoints": 0.6,
"volatilityPoints": 1
}
},
"rrPoints": 1.8,
"stopLevels": {
"symbol": "US.WST",
"rr_range": "1:1.0-1:2.5",
"risk_profile": "中等",
"stop_loss_price": 375.2958,
"strength_details": {
"ma_score": 1.5,
"atr_score": 2,
"rsi_score": 3,
"macd_score": 3,
"volume_score": 2
},
"market_adjustment": 1,
"risk_reward_ratio": 1.7,
"stop_loss_percent": 4.3,
"take_profit_price": 421.1954,
"target_multiplier": 2.2,
"technical_strength": 2.35,
"take_profit_percent": 7.4
},
"positionPoints": 1.6,
"stopLossPoints": 2.4,
"diversification": {
"score": 2,
"details": {
"method": "sector concentration proxy; no portfolio holdings used",
"sector": "Health Care",
"concentratedSectorPenalty": 0
}
},
"riskRewardRatio": 1.721772570635213,
"stopLossPercent": 4.297896322782004,
"diversificationPoints": 2
}
}
}
},
"modelVersion": "cursor_18_27_news_v2_160",
"providerErrors": [
{
"code": "VIX_MISSING",
"symbol": "US.WST",
"message": "VIX market context is required for market environment scoring",
"missing": [
"VIX"
],
"provider": "scoring"
}
],
"rankingScoreMax": 160,
"dataCompleteness": {
"complete": false,
"missingFields": [
"VIX"
],
"optionalInputs": [
"institutionalData"
],
"requiredInputs": [
"fundamentals",
"marketContext.VIX",
"marketContext.SPY",
"marketContext.QQQ",
"catalystData",
"sentimentData",
"ATR",
"sector"
],
"optionalInputWarnings": []
},
"technicalIndicators": {
"adx": 92.86,
"atr": {
"atr": 8.4271,
"rule": "ATR / current price; lower volatility scores higher",
"score": 6,
"atr_pct": 2.15
},
"cci": {
"rule": "Cursor_18.24 CCI bands",
"level": "超買或超賣風險",
"score": 2,
"value": 132.87
},
"cmf": {
"rule": "Cursor_18.24 CMF bands",
"level": "平衡",
"score": 4,
"value": 0.086
},
"kdj": {
"d": 82.76,
"j": 94.73,
"k": 86.75,
"rule": "Cursor_18.24 K/D cross",
"score": 4,
"signal": "金叉"
},
"mfi": {
"rule": "Cursor_18.24 MFI bands",
"level": "強資金流入",
"score": 10,
"value": 76.52
},
"obv": {
"rule": "Cursor_18.24 recent_slope vs previous_slope",
"score": 10,
"trend": "強流入",
"value": 3227900,
"recentSlope": 264630,
"previousSlope": -83590
},
"rsi": 66.6,
"sar": {
"rule": "Cursor_18.24 Parabolic SAR",
"score": 8,
"trend": "上升",
"value": 371.4047,
"position": "SAR喺價下",
"distancePct": 5.29,
"previousTrend": "上升"
},
"ma50": 362.0668,
"macd": {
"macd": 8.316435651077995,
"trend": "強烈看漲",
"signal": 6.7206778619611764,
"histogram": 1.5957577891168189
},
"vwap": {
"rule": "Cursor_18.24 VWAP 20D consecutive close",
"score": 10,
"value": 376.9416,
"position": "連續5日>VWAP",
"consecutiveAbove": 9
},
"volume": {
"rule": "Cursor_18.24 volume ratio",
"level": "有量",
"ratio": 1.4,
"score": 6,
"avgVolume": 513335,
"currentVolume": 718000
},
"derived": {
"ma20": 376.582,
"ma50": 362.0668,
"prevClose": 394.03,
"avgVolume10": 506520,
"avgVolume20": 513335,
"changePercent": -0.48,
"avgVolumeForScore": 513335
},
"ma_cross": {
"ma20": 376.582,
"ma50": 362.0668,
"rule": "Cursor_18.24 MA20/MA50 cross",
"cross": "多頭",
"score": 4,
"prevMa20": 375.4965,
"prevMa50": 361.147,
"spreadPct": 4.01,
"isVolumeBreakout": false
},
"bollinger": {
"lower": 356.8398,
"upper": 396.3242,
"position": "上半部"
},
"rsi_short": 84.82,
"macd_short": {
"macd": 0,
"trend": "中性",
"signal": 0,
"histogram": 0
},
"volume_ratio": {
"ratio": 1.4
}
}
}
Raw metrics JSON
{
"close": 392.15,
"volume": 718000,
"changePercent": -0.48
}
Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.